LAMP

UnknownPhase NA

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus: A Prospective, Multicenter, Randomized, Blank-controlled，Blinded End-point Study.

Lead sponsor

First Affiliated Hospital of Jinan University

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

1,708

estimated

Study population

Stroke, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Stroke (any)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03948347

Org study IDLAMP20190508

Timeline

Milestones

Study first posted2019-05-13actual

Study start2019-06-25actual

Last update posted2023-02-06actual

Primary completion2023-12estimated (month precision)

Study completion2024-06estimated (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

StrokeType 2 diabetes

Eligibility

Who can enroll

Minimum age50 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Adult subjects (male or female ≥ 50 years);

•Acute ischemic stroke patients (NIHSS ≤ 3 at the time of randomization) with type 2 diabetes mellitus within 24 hours of symptoms onset;

•High-risk TIA patients (ABCD2 score ≥ 4 at the time of randomization) with type 2 diabetes mellitus within 24 hours of onset;

•First stroke, or prior stroke without sequel (mRS score ≤ 1) and does not affect the NIHSS score;

•Informed consent signed.

Exclusion criteria

•Diagnosis of hemorrhage brain disease on baseline head CT;

•Iatrogenic and cardiogenic stroke;

•Patients receiving thrombolysis or endovascular treatment;

•Use of a GLP-1 analogue or any dipeptidyl peptidase-IV (DPP-IV) inhibitor within the 3 months prior to screening;

•Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC);

•Patients with pancreatitis or previous history of pancreatitis, inflammatory bowel disease and gastroparesis;

•Pregnant, lactating women,or patients who are likely to have a pregnancy and plan to have one;

•Allergic to liraglutide or excipients;

•Congestive heart failure (NYHA class III-IV);

•Severe liver and kidney dysfunction (AST/ALT is 3 times higher than the normal upper limit, serum creatinine is 3 times higher than the normal upper limit);

•Patients with malignant tumors who are expected to have a survival period of less than three months;

•Participated in other clinical trials of drugs within 3 months;

•Researchers believe that patients who are not suitable for this clinical study.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiovascular outcomes

Other clinical outcomes

Cardiovascular outcomes

2 endpoints

Primary/protocol endpoint

Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic)

Time frame:90 days

Stroke (any)

threshold achievement, event

SNOMED 230690007

Secondary/protocol endpoint

Percentage of patients with the 90-day new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death)

Time frame:90 days

Expanded / custom MACE composite

threshold achievement, event

componentsStroke (any), Myocardial infarction (any), Cardiovascular death

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint

Percentage of patients with the 90-day Modified Rankin Scale (mRS) ≤ 2

Time frame:90 days

threshold achievement, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial.
JAMA internal medicine2026 Jan 1PMID41182740doi:10.1001/jamainternmed.2025.5684via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.